Aya T. Soudi, Ola G. Hussein, Eman S. Elzanfaly, Hala E. Zaazaa, Mohamed Abdelkawy
Aya T. Soudi1*, Ola G. Hussein2, Eman S. Elzanfaly1, Hala E. Zaazaa1, Mohamed Abdelkawy2
1Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
2Pharmaceutical Chemistry Department, Faculty of Pharmaceutical Science and Pharmaceutical Industries, Future University in Egypt, Cairo, Egypt.
Volume - 13,
Issue - 11,
Year - 2020
Stability indicating methods are essential to determine the stability of newly developed dosage forms. In this work a simple stability-indicating thin-layer chromatographic (TLC) method was developed and validated to determine Alcaftadine in presence of its main degradation products and preservative benzalkonium chloride in bulk powder and in pharmaceutical formulations. Separation was developed on TLC aluminum plates precoated with silica gel 60F-254 as a stationary phase using chloroform: methanol: ammonia (5:5:0.1, by volume) as a developing system. Densitometric scanning was carried out in the absorbance mode at 282nm. Alcaftadine was subjected to oxidation, acid and alkaline hydrolysis. It was observed that the drug is susceptible to oxidation only. Method validation was carried out according to ICH guidelines and the proposed method was successfully applied to analyze alcaftadine in pharmaceutical dosage form with no interference from dosage form additives or preservatives. Linearity range was found to be 0.50 - 12.00µg/band with a good linear relationship r of 0.9998. Results obtained by the proposed TLC-densitometric method were statistically compared with those obtained by a reported spectrophotometric method and no differences were found.
Cite this article:
Aya T. Soudi, Ola G. Hussein, Eman S. Elzanfaly, Hala E. Zaazaa, Mohamed Abdelkawy. Stability Indicating TLC–Densitometric Method for Determination of Alcaftadine in Presence of its Degradation Products and Dosage form Preservatives. Research J. Pharm. and Tech. 2020; 13(11):5171-5176. doi: 10.5958/0974-360X.2020.00904.X
1. Poole CF, and Poole SK. Progress in densitometry for quantitation in planar chromatography. Journal of Chromatography B: Biomedical Sciences and Applications.1989; 492: p. 539-584.
2. Agrawal H, Kaul N, Paradkar AR, and Mahadik KR. Stability indicating HPTLC determination of clopidogrel bisulphate as bulk drug and in pharmaceutical dosage form. Talanta. 2003; 61(5): pp.581-589.
3. Kothapalli LP, Vighne KS, Nanda RK, and Thomas AB. Development and Validation of a Stability Indicating HPTLC Method for Estimation of Artemether in Bulk and Formulated dosage form. Asian Journal of Research in Chemistry. 2015; 8(10): pp.635-642.
4. Kumar M, Rao JR, Yadav SS, and Sathiyanarayanan L. Development and Validation of a Stability-Indicating HPTLC Method for Analysis of Bumetanide in the Bulk Drug and Tablet Dosage Form. Research Journal of Pharmacy and Technology. 2010; 3(1): pp.239-243.
5. Deshpande K, Ranaware P, Madgulkar AR, and Damle MC. Development and validation of stability indicating HPTLC method for determination of repaglinide. Research Journal of Pharmacy and Technology. 2013; 6(2): pp.158-161.
6. Rank M, Kapupara P, and Shah K. Development and validation of stability indicating HPTLC method for pioglitazone hydrochloride and metformin hydrochloride. Research Journal of Pharmacy and Technology. 2016; 9(10): pp.1555-1561.
7. Arous B, Al-Mardini MA, Ghazal H, and Al-Lahham F. Stability-Indicating Method for the Determination of Rivaroxaban and its Degradation Products using LC-MS and TLC. Research Journal of Pharmacy and Technology. 2018; 11(1): pp.212-220.
8. Renger B. Proceeding of the Sixth International Symposium on Instrumental Planar Chromatography, Institute for Chromatograghy, Bad Duerkheim. 1991; 291.
9. Sutar SV, and Yeligar VC. Degradation Kinetic Study of Melatonin in Alkaline and Acidic Medium by Validated Stability Indicating HPTLC Method. Research Journal of Pharmacy and Technology. 2020; 13(2): pp.523-528.
10. Bakshi M, and Singh S. Development of validated stability-indicating assay methods—critical review. Journal of pharmaceutical and biomedical.2002.
11. Kallepalli P, and Annapurna MM. Separation, Identification and Quantification of process related Impurities and Stress Degradants of Olaparib by LC-ESI-Q-TOF-MS. Research Journal of Pharmacy and Technology. 2018; 11(8): pp.3718-3726.
12. Sutar SV, Yeligar VC, and Patil SS. Stability Indicating Forced Degradation Studies. Research Journal of Pharmacy and Technology. 2019; 12(1): pp.429-433.
13. Kushwaha P. Significance of Stability Studies on Degradation Product. Research Journal of Pharmacy and Technology. 2009; 2(4): pp.621-627.
14. Mathew N, Jacob JT, and Nadig S. Stability Indicating Degradation Behaviour of Artesunate Under stress conditions. Research Journal of Pharmacy and Technology.2018; 11(12): pp.5587-5592.
15. Singh, Saranjit, and Bakshi M. "Guidance on the conduct of stress tests to determine inherent stability of drugs." Pharmaceutical Technology Asia. 2000; 24-24.
16. Connors KA, Amidon GL, and Stella VJ. Chemical stability of pharmaceuticals: a handbook for pharmacists. John Wiley and Sons analysis.1986; 28(6): pp.1011-1040.
17. Bohets H, McGowan C, Mannens G, Schroeder N, Edwards-Swanson K, and Shapiro A. Clinical pharmacology of alcaftadine, a novel antihistamine for the prevention of allergic conjunctivitis. Journal of ocular pharmacology and therapeutics. 2011; 27(2): pp.187-195.
18. Greiner JV, Edwards-Swanson K, and Ingerman A. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. Clinical ophthalmology (Auckland, NZ). 2011; 5: p.87.
19. Namdar R, and Valdez C. Alcaftadine: a topical antihistamine for use in allergic conjunctivitis. Drugs of today (Barcelona, Spain: 1998). 2011; 47(12): pp.883-890.
20. Chemistry Review http://www.accessdata.fda.gov/ drugsatfda_docs/nda/2010/022134s000ChemR.pdf. Accessed 16 Mar 2015).
21. Domagk G. Eine neue klasse von desinfektionsmitteln. DMW-Deutsche Medizinische Wochenschrift. 1935; 61(21): pp.829-832.
22. Baudouin C, Labbé A, Liang H, Pauly A, and Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Progress in retinal and eye research. 2010; 29(4): pp.312-334.
23. Mishra PR, Satone D, and Meshram DB. Development and Validation of HPLC Method for the Determination of Alcaftadine in Bulk Drug and its Ophthalmic Solution. J Chromatogr Sep Tech. 2016; 7(312): p.2.
24. Mishra PR, Inamdar P, Jamdar P, Patel N, Rohit M, Satone D, and Meshram DB. Development and validation of UV-spectrophotometry and the first order derivative using the area under curve method for the estimation of alcaftadine in bulk and its ophthalmic dosage form. FS J Pharm Res. 2015; 4(1): pp.9-13.
25. Chavan BB, Kalariya PD, Srinivas R. and Talluri MK. Alcaftadine: Selective Separation and Characterization of Degradation Products by LC–QTOF-MS/MS. Chromatographia. 2018; 81(4): pp.631-638.
26. Szepesi G, Gazdag M, in: J. Sherma, B. Fried (Eds.), Handbook of Thin Layer Chromatography, Marcel Dekker Inc., New York. 1996; pp. 685–703.
27. ICH.; Validation of Analytical Procedures: Methodology, ICH- Q2(R1). In: International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use. 2005.